<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372049">
  <stage>Registered</stage>
  <submitdate>16/12/2016</submitdate>
  <approvaldate>10/04/2017</approvaldate>
  <actrnumber>ACTRN12617000524392</actrnumber>
  <trial_identification>
    <studytitle>Platelet-rich plasma (PRP) local injection for female sexual dysfunction</studytitle>
    <scientifictitle>Platelet- rich plasma (PRP) local injection for female sexual dysfunction</scientifictitle>
    <utrn>U1111-1191-0080</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition> Sexual dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A small sample of blood (5ml) is withdrawn from the patient, then spun in a centrifuge to separate the blood into layers. The platelet-rich plasma layer is carefully extracted, then injected back into the anterior and posterior vaginal wall, G-spot and clitoris. the procedure will take about 10 minutes after local anaesthetic cream application.procedure will be done in the outpatient clinic by gynaecology specialist with minimum 3 years experience.patients will receive four times injections 2weeks a part.they will be evaluated by FSFI questionnaire after 2  months.</interventions>
    <comparator>No control group' in this field</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>change in sexual function accessed by  FSFIq before and after the procedure.</outcome>
      <timepoint>2 months after PRP injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1-The incidence of vaginal infection assessed by self-report.
</outcome>
      <timepoint>2 months after PRP injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2-change in urinary incontinence in patients complaining of incontinence.
will be assessed by ICIQ short form questionnaire.</outcome>
      <timepoint>2 months after PRP injection</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>sexually active females 18-60 years complaining of sexual dysfunction.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1- psychological or mental illness.
2- male partner erectile dysfunction.
3- diabetic patients
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>pilot study 
Statistical presentation and analysis of the study will be conducted using mean, standard deviation and chi-square test .</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>20/04/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>20/08/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>DOAA MOHAMED SALEH</primarysponsorname>
    <primarysponsoraddress>ALZAHRAA UNIVEISITY HOSPITSL
ABASSIA
CAIRO
EGYPT 
AZHAR UNIVERSITY </primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>AL ZAHRAA UNIVERSITY HOSPITAL</fundingname>
      <fundingaddress>AL ZAHRAA UNIVERISITY HOSPITAL
CAIRO
ABASSIA
 AZHAR UNIVERSITY </fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>TAISEER MAROUF</sponsorname>
      <sponsoraddress>PROFESSOR OB/GYN
AL ZAHRAA UNIVEROSITY HOSPITAL
ABASSIA 
CAIRO</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Platelet Rich Plasma (PRP) has been demonstrated to be effective and without serious side effects in multiple studies in the areas of wound care, orthopaedics, dental surgery and in a variety of cosmetic procedures.
 PRP activates pluripotent stem cells in the area of injection resulting in rejuvenation and even enhancement of damaged or undamaged tissue. The aqueous nature of PRP allows injection through a small bore needle and an even distribution throughout the tissue surrounding the injection site.  
women who presented with complaints of dyspareunia or other symptoms related to sexual dysfunction will be offered PRP injections into the periurethral area of the Skene's glands, vaginal wall
and the clitoris and will be observed for their responses to this treatment.
It will offer a cheap, easy, non-invasive and safe treatment for females with sexual dysfunction.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not required</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>doaa mohamed saleh</name>
      <address>AL ZAHRAA UNIVERISITY HOSPITAL,AZHAR UNIVERISITY
ABASSIA
 ,Cairo
,EGYPT </address>
      <phone>+201096565703</phone>
      <fax />
      <email>dr.dodogyn@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>taiseer marouf</name>
      <address>PROFESSOR OB/GYN 
AZHAR UNIVERSITY
AL ZAHRA UNIVERISITY HOSPITAL
 ,CAIRO
,EGYPT</address>
      <phone>+201223660078</phone>
      <fax />
      <email>taiseer.maarouf@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>nahed ezzat</name>
      <address>assistantprofessor OB/GYN
AZHAR UNIVERSITY
AL ZAHRA UNIVERISITY HOSPITAL
 CAIRO
,EGYPT</address>
      <phone>+20122654789</phone>
      <fax />
      <email>nahedallam16@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone>0</phone>
      <fax />
      <email />
      <country>Egypt</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>